LOX-1 Emerges as a Promising but Unproven Target in Fibrotic Disease

Fibrotic diseases, in which organs accumulate excessive extracellular matrix and progressively lose function, still lack therapies that can prevent, reverse or cure established scarring. A review published in Cell Biology and Toxicology examines one emerging candidate for closing that gap: lectin-like oxidized low-density lipoprotein receptor-1, known as LOX-1, and asks whether it can serve as both a biomarker and a therapeutic target in fibrosis.

The review, authored by Melkamu Tilahun, Mohammed Jemal and colleagues and published online on 27 October 2026 as an open-access article, brings together experimental and clinical evidence on LOX-1’s involvement in fibrotic remodeling across major organs. The authors emphasize from the outset that LOX-1’s contribution appears to vary across organs and disease contexts, and that the strength and mechanistic specificity of the evidence differ considerably among tissues and disease models.

According to the review, LOX-1 is associated with fibrotic remodeling through a set of interconnected mechanisms. These include oxidative stress, inflammation, injury to endothelial and epithelial cells, activation of fibroblasts and their contractile derivatives, myofibroblasts, dysregulated TGF-β/SMAD and related signaling pathways, and altered turnover of extracellular matrix.

The article also evaluates circulating soluble LOX-1, or sLOX-1, as a potential biomarker. The authors report that sLOX-1 shows promise as a complementary marker alongside established indicators in multimarker panels for assessing fibrosis. They are careful, however, to note that its specificity and clinical utility for fibrosis remain uncertain, meaning that elevated or altered levels cannot yet be relied upon to diagnose or monitor fibrotic disease in routine practice.

The review notes that several direct and indirect LOX-1-targeted therapeutic approaches are emerging, but the authors stress that their antifibrotic efficacy, safety and clinical applicability remain to be established. No LOX-1-targeted antifibrotic therapy has yet been validated in patients.

The overall conclusion is measured: LOX-1 represents a promising but incompletely validated biomarker and therapeutic target in fibrotic diseases. The review does not claim that blocking or measuring LOX-1 will change outcomes for patients today; rather, it maps where the evidence stands and where it falls short.

To move the field forward, the authors call for further cell- and tissue-specific mechanistic studies, multi-omics and spatial investigations, rigorous biomarker validation, and well-designed clinical trials. Only such work, they argue, can clarify LOX-1’s diagnostic, prognostic and therapeutic utility and its potential role in individualized antifibrotic treatment.

For readers following fibrosis research, the review’s message is that LOX-1 is a hypothesis worth testing rather than a proven answer. Its links to oxidative stress, inflammation, endothelial injury and myofibroblast activation make it biologically plausible across organs, but the variability of evidence between tissues, the uncertain specificity of soluble LOX-1 as a marker, and the untested safety and efficacy of targeted therapies all mean that clinical translation remains a future goal, not a present reality.

Subject of Research: The role of the oxidized low-density lipoprotein receptor LOX-1 in fibrotic diseases and its potential as a biomarker and therapeutic target.

Article Title: Mechanistic roles of oxidized low density lipoprotein receptor 1(LOX-1) in fibrotic diseases and its diagnostic and therapeutic implications

Article References: Tilahun, M., Adugna, A., Baylie, T., Yeneneh, N. A., Dessalegn, M., Amha, H., Abawa, E. D., Mekete, Y. S., Liyew, W. A., Ashenef, B., Abebaw, D., Asefa, B. L., & Jemal, M. (2026). Mechanistic roles of oxidized low density lipoprotein receptor 1(LOX-1) in fibrotic diseases and its diagnostic and therapeutic implications. Cell Biology and Toxicology. https://doi.org/10.1007/s10565-026-10314-9

Image Credits: AI Generated

DOI: 10.1007/s10565-026-10314-9

Keywords: fibrosis, LOX-1, oxidized LDL receptor, biomarker, sLOX-1, TGF-beta, extracellular matrix, myofibroblast, review, organ fibrosis, Mechanistic, roles